Formulations of hormone therapy and risk of Parkinson disease
Identifieur interne : 000580 ( Main/Exploration ); précédent : 000579; suivant : 000581Formulations of hormone therapy and risk of Parkinson disease
Auteurs : Jessica I. Lundin [États-Unis] ; Thanh G. N. Ton [États-Unis] ; Andrea Z. Lacroix [États-Unis] ; W. T. Longstreth [États-Unis] ; Gary M. Franklin [États-Unis] ; Phillip D. Swanson [États-Unis] ; Terri Smith-Weller [États-Unis] ; Brad A. Racette [États-Unis] ; Harvey Checkoway [États-Unis]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2014.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Estrogens, Esterified (USP), Progestins.
- adverse effects : Estrogen Replacement Therapy.
- etiology : Parkinson Disease.
- chemical , therapeutic use : Estrogens, Esterified (USP).
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Female, Humans, Middle Aged.
Abstract
Hormone therapy (HT) is a class of medications widely prescribed to women in the Western world. Evidence from animal models and in vitro studies suggests that estrogen may protect against nigrostriatal system injury and increase dopamine synthesis, metabolism, and transport. Existing epidemiologic research indicates a possible reduced risk of Parkinson disease (PD) associated with HT use. The objective of this study was to evaluate PD risk associated with specific HT formulations.
Neurologist confirmed cases and age-matched controls were identified from Group Health Cooperative (GHC) of Washington state. Final analysis included 137 female cases and 227 controls. HT use was ascertained from the GHC pharmacy database, further classified as conjugated estrogens, esterified estrogens, and progestin.
Ever use of HT formulation demonstrated a suggested elevated risk with esterified estrogen use (OR, 3.1; 95% CI, 1.0–9.8), and no risk associated with conjugated estrogen use (OR, 0.6; 95% CI, 0.6–1.3). Restricting this analysis to prescriptions that included progestin further elevated the risk associated with esterified estrogen use (OR, 6.9; 95% CI, 2.1–22.9); again, no risk was associated with conjugated estrogen use (OR, 1.7; 95% CI, 0.6–5.0).
The findings from this study suggest an increase in PD risk associated with esterified estrogen use combined with progestin, and no risk associated with conjugated estrogen with progestin. These findings could have important implications for choice of HT in clinical practice.
Url:
DOI: 10.1002/mds.26037
PubMed: 25255692
PubMed Central: 4216612
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000420
- to stream Pmc, to step Curation: 000420
- to stream Pmc, to step Checkpoint: 000034
- to stream PubMed, to step Corpus: 000381
- to stream PubMed, to step Curation: 000381
- to stream PubMed, to step Checkpoint: 000591
- to stream Ncbi, to step Merge: 004122
- to stream Ncbi, to step Curation: 004122
- to stream Ncbi, to step Checkpoint: 004122
- to stream Main, to step Merge: 000580
- to stream Main, to step Curation: 000580
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Formulations of hormone therapy and risk of Parkinson disease</title><author><name sortKey="Lundin, Jessica I" sort="Lundin, Jessica I" uniqKey="Lundin J" first="Jessica I." last="Lundin">Jessica I. Lundin</name><affiliation wicri:level="4"><nlm:aff id="A1">Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Ton, Thanh G N" sort="Ton, Thanh G N" uniqKey="Ton T" first="Thanh G. N." last="Ton">Thanh G. N. Ton</name><affiliation wicri:level="4"><nlm:aff id="A2">Department of Neurology, University of Washington, Seattle, Washington, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Lacroix, Andrea Z" sort="Lacroix, Andrea Z" uniqKey="Lacroix A" first="Andrea Z." last="Lacroix">Andrea Z. Lacroix</name><affiliation wicri:level="2"><nlm:aff id="A3">Department of Family and Preventive Medicine, University of California San Diego, La Jolla, CA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Family and Preventive Medicine, University of California San Diego, La Jolla, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Longstreth, W T" sort="Longstreth, W T" uniqKey="Longstreth W" first="W. T." last="Longstreth">W. T. Longstreth</name><affiliation wicri:level="4"><nlm:aff id="A2">Department of Neurology, University of Washington, Seattle, Washington, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation><affiliation wicri:level="4"><nlm:aff id="A4">Department of Epidemiology, University of Washington, Seattle, Washington, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Franklin, Gary M" sort="Franklin, Gary M" uniqKey="Franklin G" first="Gary M." last="Franklin">Gary M. Franklin</name><affiliation wicri:level="4"><nlm:aff id="A1">Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation><affiliation wicri:level="4"><nlm:aff id="A2">Department of Neurology, University of Washington, Seattle, Washington, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Swanson, Phillip D" sort="Swanson, Phillip D" uniqKey="Swanson P" first="Phillip D." last="Swanson">Phillip D. Swanson</name><affiliation wicri:level="4"><nlm:aff id="A2">Department of Neurology, University of Washington, Seattle, Washington, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Smith Weller, Terri" sort="Smith Weller, Terri" uniqKey="Smith Weller T" first="Terri" last="Smith-Weller">Terri Smith-Weller</name><affiliation wicri:level="4"><nlm:aff id="A1">Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A." last="Racette">Brad A. Racette</name><affiliation wicri:level="2"><nlm:aff id="A5">Department of Neurology, Washington University, St. Louis, Missouri, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Washington University, St. Louis, Missouri</wicri:regionArea><placeName><region type="state">Missouri (État)</region></placeName></affiliation></author><author><name sortKey="Checkoway, Harvey" sort="Checkoway, Harvey" uniqKey="Checkoway H" first="Harvey" last="Checkoway">Harvey Checkoway</name><affiliation wicri:level="2"><nlm:aff id="A3">Department of Family and Preventive Medicine, University of California San Diego, La Jolla, CA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Family and Preventive Medicine, University of California San Diego, La Jolla, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">25255692</idno><idno type="pmc">4216612</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216612</idno><idno type="RBID">PMC:4216612</idno><idno type="doi">10.1002/mds.26037</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">000420</idno><idno type="wicri:Area/Pmc/Curation">000420</idno><idno type="wicri:Area/Pmc/Checkpoint">000034</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">000381</idno><idno type="wicri:Area/PubMed/Curation">000381</idno><idno type="wicri:Area/PubMed/Checkpoint">000591</idno><idno type="wicri:Area/Ncbi/Merge">004122</idno><idno type="wicri:Area/Ncbi/Curation">004122</idno><idno type="wicri:Area/Ncbi/Checkpoint">004122</idno><idno type="wicri:doubleKey">0885-3185:2014:Lundin J:formulations:of:hormone</idno><idno type="wicri:Area/Main/Merge">000580</idno><idno type="wicri:Area/Main/Curation">000580</idno><idno type="wicri:Area/Main/Exploration">000580</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Formulations of hormone therapy and risk of Parkinson disease</title><author><name sortKey="Lundin, Jessica I" sort="Lundin, Jessica I" uniqKey="Lundin J" first="Jessica I." last="Lundin">Jessica I. Lundin</name><affiliation wicri:level="4"><nlm:aff id="A1">Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Ton, Thanh G N" sort="Ton, Thanh G N" uniqKey="Ton T" first="Thanh G. N." last="Ton">Thanh G. N. Ton</name><affiliation wicri:level="4"><nlm:aff id="A2">Department of Neurology, University of Washington, Seattle, Washington, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Lacroix, Andrea Z" sort="Lacroix, Andrea Z" uniqKey="Lacroix A" first="Andrea Z." last="Lacroix">Andrea Z. Lacroix</name><affiliation wicri:level="2"><nlm:aff id="A3">Department of Family and Preventive Medicine, University of California San Diego, La Jolla, CA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Family and Preventive Medicine, University of California San Diego, La Jolla, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Longstreth, W T" sort="Longstreth, W T" uniqKey="Longstreth W" first="W. T." last="Longstreth">W. T. Longstreth</name><affiliation wicri:level="4"><nlm:aff id="A2">Department of Neurology, University of Washington, Seattle, Washington, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation><affiliation wicri:level="4"><nlm:aff id="A4">Department of Epidemiology, University of Washington, Seattle, Washington, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Franklin, Gary M" sort="Franklin, Gary M" uniqKey="Franklin G" first="Gary M." last="Franklin">Gary M. Franklin</name><affiliation wicri:level="4"><nlm:aff id="A1">Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation><affiliation wicri:level="4"><nlm:aff id="A2">Department of Neurology, University of Washington, Seattle, Washington, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Swanson, Phillip D" sort="Swanson, Phillip D" uniqKey="Swanson P" first="Phillip D." last="Swanson">Phillip D. Swanson</name><affiliation wicri:level="4"><nlm:aff id="A2">Department of Neurology, University of Washington, Seattle, Washington, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Smith Weller, Terri" sort="Smith Weller, Terri" uniqKey="Smith Weller T" first="Terri" last="Smith-Weller">Terri Smith-Weller</name><affiliation wicri:level="4"><nlm:aff id="A1">Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A." last="Racette">Brad A. Racette</name><affiliation wicri:level="2"><nlm:aff id="A5">Department of Neurology, Washington University, St. Louis, Missouri, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Washington University, St. Louis, Missouri</wicri:regionArea><placeName><region type="state">Missouri (État)</region></placeName></affiliation></author><author><name sortKey="Checkoway, Harvey" sort="Checkoway, Harvey" uniqKey="Checkoway H" first="Harvey" last="Checkoway">Harvey Checkoway</name><affiliation wicri:level="2"><nlm:aff id="A3">Department of Family and Preventive Medicine, University of California San Diego, La Jolla, CA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Family and Preventive Medicine, University of California San Diego, La Jolla, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Estrogen Replacement Therapy (adverse effects)</term><term>Estrogens, Esterified (USP) (adverse effects)</term><term>Estrogens, Esterified (USP) (therapeutic use)</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Parkinson Disease (etiology)</term><term>Progestins (adverse effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Estrogens, Esterified (USP)</term><term>Progestins</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Estrogen Replacement Therapy</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Estrogens, Esterified (USP)</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Female</term><term>Humans</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="S1"><title>Background</title><p id="P1">Hormone therapy (HT) is a class of medications widely prescribed to women in the Western world. Evidence from animal models and in vitro studies suggests that estrogen may protect against nigrostriatal system injury and increase dopamine synthesis, metabolism, and transport. Existing epidemiologic research indicates a possible reduced risk of Parkinson disease (PD) associated with HT use. The objective of this study was to evaluate PD risk associated with specific HT formulations.</p></sec><sec id="S2"><title>Methods</title><p id="P2">Neurologist confirmed cases and age-matched controls were identified from Group Health Cooperative (GHC) of Washington state. Final analysis included 137 female cases and 227 controls. HT use was ascertained from the GHC pharmacy database, further classified as conjugated estrogens, esterified estrogens, and progestin.</p></sec><sec id="S3"><title>Results</title><p id="P3">Ever use of HT formulation demonstrated a suggested elevated risk with esterified estrogen use (OR, 3.1; 95% CI, 1.0–9.8), and no risk associated with conjugated estrogen use (OR, 0.6; 95% CI, 0.6–1.3). Restricting this analysis to prescriptions that included progestin further elevated the risk associated with esterified estrogen use (OR, 6.9; 95% CI, 2.1–22.9); again, no risk was associated with conjugated estrogen use (OR, 1.7; 95% CI, 0.6–5.0).</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">The findings from this study suggest an increase in PD risk associated with esterified estrogen use combined with progestin, and no risk associated with conjugated estrogen with progestin. These findings could have important implications for choice of HT in clinical practice.</p></sec></div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Missouri (État)</li><li>Washington (État)</li></region><settlement><li>Seattle</li></settlement><orgName><li>Université de Washington</li></orgName></list><tree><country name="États-Unis"><region name="Washington (État)"><name sortKey="Lundin, Jessica I" sort="Lundin, Jessica I" uniqKey="Lundin J" first="Jessica I." last="Lundin">Jessica I. Lundin</name></region><name sortKey="Checkoway, Harvey" sort="Checkoway, Harvey" uniqKey="Checkoway H" first="Harvey" last="Checkoway">Harvey Checkoway</name><name sortKey="Franklin, Gary M" sort="Franklin, Gary M" uniqKey="Franklin G" first="Gary M." last="Franklin">Gary M. Franklin</name><name sortKey="Franklin, Gary M" sort="Franklin, Gary M" uniqKey="Franklin G" first="Gary M." last="Franklin">Gary M. Franklin</name><name sortKey="Lacroix, Andrea Z" sort="Lacroix, Andrea Z" uniqKey="Lacroix A" first="Andrea Z." last="Lacroix">Andrea Z. Lacroix</name><name sortKey="Longstreth, W T" sort="Longstreth, W T" uniqKey="Longstreth W" first="W. T." last="Longstreth">W. T. Longstreth</name><name sortKey="Longstreth, W T" sort="Longstreth, W T" uniqKey="Longstreth W" first="W. T." last="Longstreth">W. T. Longstreth</name><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A." last="Racette">Brad A. Racette</name><name sortKey="Smith Weller, Terri" sort="Smith Weller, Terri" uniqKey="Smith Weller T" first="Terri" last="Smith-Weller">Terri Smith-Weller</name><name sortKey="Swanson, Phillip D" sort="Swanson, Phillip D" uniqKey="Swanson P" first="Phillip D." last="Swanson">Phillip D. Swanson</name><name sortKey="Ton, Thanh G N" sort="Ton, Thanh G N" uniqKey="Ton T" first="Thanh G. N." last="Ton">Thanh G. N. Ton</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000580 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000580 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:4216612
|texte= Formulations of hormone therapy and risk of Parkinson disease
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25255692" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |